Abstract Serum levels of amphiregulin and transforming growth factor-α (TGF-α), which were identified previously to be expressed at high in non–small cell lung cancer (NSCLC) with poor response gefitinib, examined by ELISA using blood samples taken from 50 patients advanced NSCLCs. Of 14 cases that revealed above the cutoff line for serum, 12 responded poorly whereas 18 36 showing below partial (PR) or stable disease (SD; P = 0.026). Thirteen 15 who positive TGF-α 35 negative turned out...

To characterize the molecular mechanisms involved in carcinogenesis and progression of small-cell lung cancer (SCLC) identify molecules to be applied as novel diagnostic markers and/or for development molecular-targeted drugs, we cDNA microarray profile analysis coupled with purification cells by laser-microbeam microdissection (LMM). Expression profiles 32,256 genes 15 SCLCs identified 252 that were commonly up-regulated 851 transcripts down-regulated SCLC compared non-cancerous tissue...

Abstract Purpose and Experimental Design: To identify molecules that might be useful as diagnostic/prognostic biomarkers targets for the development of new molecular therapies, we screened genes were highly transactivated in a large proportion 101 lung cancers by means cDNA microarray representing 27,648 genes. We found gene encoding KIF4A, kinesin family member 4A, one such candidates. Tumor tissue was applied to examine expression KIF4A protein its clinicopathologic significance archival...

To identify molecules that might serve as biomarkers or targets for development of novel molecular therapies, we have been screening genes encoding transmembrane/secretory proteins are up‐regulated in lung cancers, using cDNA microarrays coupled with purification tumor cells by laser microdissection. A gene seizure‐related 6 homolog (mouse)‐like 2 (SEZ6L2) protein, was chosen a candidate such molecule. Semi‐quantitative RT‐PCR and western‐blot analyses documented increased expression SEZ6L2...

We present the case of a 79-year-old man who showed multiple pulmonary nodules on chest computed tomography (CT) after being treated for 6 months with ruxolitinib, an inhibitor Janus kinase (JAK) 1 and 2, to treat primary myelofibrosis. examined lesions by bronchoscopy, biopsy specimen revealed fungus bodies Cryptococcus granulomatous inflammation. As result, patient was diagnosed cryptococcosis. The fluconazole (200 mg daily 2 weeks) concomitant ruxolitinib administration, but progressed....

Chronic fibrosing idiopathic interstitial pneumonia (IIP) is characterized by alveolar epithelial damage, activation of fibroblast proliferation, and loss normal pulmonary architecture function. This study aims to investigate the genetic backgrounds IIP through gene expression profiling pathway analysis, identify potential biomarkers that can aid in diagnosis serve as novel therapeutic targets. RNA extracted from lung specimens 12 patients with chronic was profiled using Illumina Human WG-6...

A 72-year-old man was admitted to our hospital undergo a novel small-intestinal endoscopic procedure. He had occasional episodes of hematochezia over 2-year period, during which he been hospitalized twice previously. However, numerous investigations, including hematological and biochemical studies, gastroscopy, colonoscopy, computed tomography, scintigraphy, angiography failed detect the source bleeding in gastrointestinal tract. On this admission, double-balloon enteroscopy performed...

Background: Nivolumab is an immune checkpoint inhibitor that has shown efficacy for treating non-small cell lung cancer and become a standard therapy previously treated cancer. Moreover, immune-related adverse events of are well-known. Malignant pericardial effusions occasionally arise in patients with There have been few reports effusion after nivolumab administration. However, the cause this condition controversial; possibilities include serositis as event or pseudo-progression. Case...

Atezolizumab is an immune checkpoint inhibitor that a key drug in non-small-cell lung cancer treatment. However, it can cause immune-related adverse events, including liver injury. Several patterns of injury associated with therapy have been reported; however, not much known about sclerosing cholangitis. We present here case adenocarcinoma atezolizumab-induced secondary cholangitis diagnosed using needle biopsy the liver. A 77-year-old woman adenocarcinoma, cT3N2M0, stage IIIA, was treated...

Background Classical Hodgkin's lymphoma is characterized by Hodgkin and Reed Sternberg cells, which are of B-cell origin in many cases. We recently highlighted the adverse prognostic significance cytotoxic molecule expression patients with classical lymphoma. However, clinical characteristics molecule-positive remain controversial.Design Methods investigated clinicopathological profiles 32 lymphoma, comprising 23 nodular sclerosis 9 mixed cellularity, compared these those 55 nodal peripheral...

The incorporation of rituximab in immunochemotherapy has improved treatment outcomes for diffuse large B-cell lymphoma, but the prognosis some lymphomas remains dismal. Identification adverse prognostic subgroups is essential choice appropriate therapeutic strategy.We retrospectively investigated impact so-called 'double-hit' cytogenetic abnormalities, i.e. abnormalities involving c-MYC co-existing with other poor BCL2, BCL6 or BACH2, on 93 consecutive lymphoma patients.According to revised...

Only a few cases of putative lung adenocarcinoma presenting as carcinoma unknown primary site (CUP) with epidermal growth factor receptor (EGFR) mutation have been reported, and the efficacy EGFR-tyrosine kinase inhibitors (TKIs) for these is unclear.A 67-year-old man complained paresis right lower extremity, dysarthria, memory disturbance. Computed tomography magnetic resonance imaging showed multiple brain tumors edema swelling left supraclavicular, mediastinal, upper abdominal lymph...

We herein report the rare case of co-occurring dermatomyositis (DM), interstitial pneumonia (IP), and lung cancer in a 59-year-old man. Computed tomography (CT) positron emission tomography-CT showed presence left tumor with IP, which was diagnosed as adenocarcinoma by CT-guided biopsy. DM based on myalgia, Gottron's papules, anti-aminoacyl-tRNA synthetase antibody positivity patient. Co-occurrence above-mentioned three diseases is rare, acute exacerbation IP major cause death such cases....

Gefitinib and erlotinib are efficacious safe for older patients with epidermal growth factor receptor-mutant non-small cell lung cancer. However, prolonged use of receptor-tyrosine kinase inhibitors in is difficult, owing to potential adverse events. Hence, dose reduction or treatment discontinuation often required. We investigated the efficacy low-dose first-line its effects on quality life cancer.A prospective, multicenter, phase II clinical trial was carried out aged ≥75 years Initially,...

Nivolumab is an immune checkpoint inhibitor with demonstrated efficacy against several malignant tumors. Alterations in driver oncogenes such as EGFR and ALK are a poor prognostic factor nivolumab therapy for non-small cell lung cancer (NSCLC), whereas smoking history well-known, favorable factor. However, of multiple primary tumors (MPMTs) has not been reported, its oncogene-positive NSCLC smokers unclear. Herein, we report the case patient heavy who developed synchronous ALK-positive...

Cytogenetic studies were performed on a group of 32 patients with myelodysplastic syndrome (MDS). Five had refractory anemia (RA), four RA ring sideroblasts (RARS), nine excess blasts (RAEB), eight RAEB 'in transformation' (RAEB-T), three chronic myelomonocytic leukemia (CMML) and secondary MDS (SMDS). Two in the SMDS been treated alkylating agents for lung cancer polycythemia vera, respectively. The other exposed to thorotrast. Chromosome analyses Q G bandings bone marrow cells incubated 24...

Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus paclitaxel. However, because rarity standard regimen has not yet established. Here, we report a case thymic carcinoma that responded to first-line nanoparticle albumin-bound paclitaxel (<i>nab</i>-paclitaxel) therapy with continuation maintenance <i>nab</i>-paclitaxel...

Carcinoma of unknown primary site (CUP) is diagnosed only in 2-9% all cancer cases. Adenocarcinomas account for approximately 60% CUP, and some these are putative lung adenocarcinomas. The frequency driver oncogene positivity the adenocarcinomas unknown, efficacy targeting therapies also unknown. This first case report C-ros 1 (ROS1)-rearranged adenocarcinoma presenting as CUP showing a good response to ROS1 inhibitor therapy. A 55-year-old woman presented with neck lymphadenopathy. Computed...